This is an old revision of the document!
Migraine
Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.
| Condition(s) | Type of Drug | Phase | Add-On | Placebo | Duration | Open-Label Extension |
|---|---|---|---|---|---|---|
| Adult episodic migraine preventive | Novel oral gepant | III | Yes | 50% | 24 weeks | |
| Adult episodic migraine preventive + abortive | Atogepant + Ubrogepant | IV | No | 0% | 52 weeks |
Response Form
If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!
| Joshua A. Tobin, MD, Director of Migraine Research |
| Stephen S. Flitman, MD, Medical Director |
